NewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Rating of “Buy” from Analysts

NewAmsterdam Pharma (NASDAQ:NAMS) has received a consensus rating of “Buy” from the six brokerages that are currently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $39.80.

A number of equities analysts recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. HC Wainwright restated a “buy” rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Piper Sandler restated an “overweight” rating and issued a $37.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Finally, Scotiabank upped their price target on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research report on Wednesday, December 11th.

NewAmsterdam Pharma Trading Up 0.6 %

NAMS stock opened at $23.55 on Monday. The company has a 50 day simple moving average of $23.68 and a 200 day simple moving average of $19.81. NewAmsterdam Pharma has a 1 year low of $15.19 and a 1 year high of $27.29.

Insider Activity

In other news, major shareholder Nap B.V. Forgrowth sold 166,011 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $25.39, for a total value of $4,215,019.29. Following the sale, the insider now directly owns 11,150,461 shares of the company’s stock, valued at approximately $283,110,204.79. This represents a 1.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last three months, insiders have sold 446,730 shares of company stock valued at $11,438,695. 19.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its stake in shares of NewAmsterdam Pharma by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock valued at $1,433,000 after purchasing an additional 1,399 shares during the last quarter. Quarry LP boosted its stake in NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after acquiring an additional 6,247 shares in the last quarter. Barclays PLC boosted its stake in NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after acquiring an additional 7,199 shares in the last quarter. Bellevue Group AG bought a new position in NewAmsterdam Pharma during the third quarter worth $128,000. Finally, Sei Investments Co. boosted its stake in NewAmsterdam Pharma by 49.1% during the second quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock worth $472,000 after acquiring an additional 8,087 shares in the last quarter. 89.89% of the stock is owned by institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.